Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $1,062,000.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CEO Emil D. Kakkis sold 25,000 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now owns 2,158,985 shares of the company's stock, valued at approximately $91,713,682.80. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ultragenyx Pharmaceutical Trading Down 3.5 %

Shares of Ultragenyx Pharmaceutical stock traded down $1.40 on Friday, reaching $38.62. The stock had a trading volume of 724,201 shares, compared to its average volume of 782,526. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The company has a market cap of $3.57 billion, a P/E ratio of -6.09 and a beta of 0.60. The business's 50 day moving average is $42.57 and its two-hundred day moving average is $48.72.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Wells Fargo & Company increased their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Wedbush reaffirmed a "neutral" rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Finally, Canaccord Genuity Group upped their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $93.50.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter worth about $5,505,000. Mackenzie Financial Corp raised its stake in Ultragenyx Pharmaceutical by 275.6% in the fourth quarter. Mackenzie Financial Corp now owns 16,115 shares of the biopharmaceutical company's stock valued at $678,000 after purchasing an additional 11,825 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $82,000. Frazier Life Sciences Management L.P. raised its stake in Ultragenyx Pharmaceutical by 3.9% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 658,715 shares of the biopharmaceutical company's stock valued at $27,712,000 after purchasing an additional 25,000 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Ultragenyx Pharmaceutical by 13.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,376 shares of the biopharmaceutical company's stock valued at $8,514,000 after purchasing an additional 24,620 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.